Glaucoma- POAG Flashcards
Normal range for IOP
13-21 mmHg
NT glaucoma classification
Normal IOP with glaucomatous changes
Glaucoma classification
Elevated IOP with glaucomatous changes
Ocular HTN classification
Elevated IOP with no glaucomatous changes
Risk factors for POAG
Age (>60, >40 for Black patients) Elevated IOP (>21) Ethnicity (Blacks and Hispanics) Increased cup-to-disk ratio Family history Central corneal thickness (thinner is at an increased risk) Ocular perfusion pressure (lower is at an increased risk) T2DM Myopia (near-sightedness)
Who to treat for glaucoma
All patients with elevated IOP AND confirmed disc changes/field defects
All patients with ocular HTN AND at least 2 risk factors
All patients with NT glaucoma AND documented progression of visual field loss
Glaucoma treatment goals
PRESERVE THE NERVE
Lower IOP ≥25% below pretreatment IOP
Surgery for glaucoma
Mainstay of treatment (more effective at lowering IOP) but more expensive and invasive
QOL differences with glaucoma surgery
Increased risk of cataract formation, loss of visual acuity and local eye Sx infrequent but higher in surgical patients
How to choose a glaucoma med
Choose a drug and regiment that have minimal impact on QOL and vision
Prostaglandin analog drugs
Bimatoprost, latanoprost, latanoprostene bunod
How much do prostaglandin analogs lower IOP?
25-33%
Bimatoprost pearls
Best efficacy, but worst side effects in generic 0.03% formulation. Lumigan is 0.1% and has a better side effect profile but still brand name regardless
Latanoprost pearl
Most popular generic
PA ADEs
Red eyes, hypertrichosis (eyelash growth), systemic infection, headache, eye color changes (iris)
PA CIs
macular edema, iritis, uveitis, keratitis
Beta-blocker drugs
Betaxolol, cartelol, levobunolol, metiprandolol, timolol
How much do beta-blockers lower IOP?
20-25%
Betaxolol pearls
Selective, use in patients with COPD (as an example)
Cartelol pearl
Moderate intrinsic sympathomimetic activity
Beta-blocker ADEs
Local irritation, cardiac, pulmonary, and CNS side effects, tachyphylaxis
Beta-blocker CIs
Absolute: sinus bradycardia, heart block, HF
Relative: pulmonary disease
Alpha-2 adrenergic agonist drug
Brimonidine
Brimonidine pearls
Not recommended as a single agent (usually combined with timolol)
When does brimonidine become a first-line option?
When PAs and beta-blockers are CI’ed
Brimonidine IOP lowering
20-25%
Brimonidine ADEs
conjunctival hyperemia, irritation, allergic reactions, drowsiness, xerostomia (dry mouth), tachyphylaxis
Brimonidine precaution
CV diseases
Carbonic anhydrase inhibitor drugs
Acetazolamide, brinzolamide, dorzolamide, methazolamide
Acetazolamide and metazolamide are available in what formulation?
PO
Brinzolamide is also available in combination with what other drug?
Brimonidine
Dorzolamide is also available in combination with what other drug?
Timolol
Carbonic anhydrase inhibitor ADEs
Favorable side effect profile overall, can be good for patients who don’t like the side effects of other meds
When can you use the dorzolamide/timolol combo?
If bimatoprost isn’t tolerated
Carbonic anhydrase inhibitors decrease IOP by how much?
15-20% for topical formulations
20-30% for PO formulations
Rho kinase inhibitor drugs
Netarsudil (Rhopressa), Rocklatan (netarsudil and latanoprost)
Rho kinase inhibitor IOP lowering
~20% if IOP <27
Rho kinase inhibitors ADEs
Hyperemia, conjunctival hemorrhage
When are rho kinase inhibitors used?
Used as a last-line option and as an add-on drug
Overall treatment options for POAG (what should you take into account when picking a med for a patient?)
Fewest drugs at the lowest concentrations
Stress convenience and adherence
Counsel on nasolacrimal occlusion
Not at goal? Switch if adherence or tolerance issues, poor efficacy, add a drug if one is helping but not at goal yet
First-line treatment options for POAG
PAs and beta-blockers
Second-line treatment options for POAG
Dorzolamide+timolol
Brimonidine (but becomes 1st line if patient has CIs)
Brinzolamide, dorzolamide alone, PO carbonic anhydrase inhibitors (acetazolamide and methazolamide)
Netarsudil/Rhopressa
Progression risk factors
Increasing IOP, older age, disc hemorrhage, larger cup-to-disk ratio, thinner central cornea, lower ocular perfusion pressure, poor adherence to meds, progression in the other eye